Related Experiment Video
Updated: Sep 23, 2025
An Electrochemiluminescence-Based Assay for MeCP2 Protein Variants
Published on: May 22, 2020
Expression, Purification, Characterization and Cellular Uptake of MeCP2 Variants.
Alexander V Beribisky1, Hannes Steinkellner2, Sofia Geislberger2
1Institute of Medical Genetics, Center for Pathobiochemistry and Genetics, Medical University of Vienna, Währinger Straße 10, A-1090, Vienna, Austria. alexander.beribisky@meduniwien.ac.at.
Researchers developed a potential therapy for Rett Syndrome by delivering functional Methyl-CpG-binding protein 2 (MeCP2) using a cell-penetrating peptide. This protein replacement therapy successfully entered cells and reached the nucleus, showing promise for treating this neurodevelopmental disorder.
Area of Science:
- Neuroscience
- Molecular Biology
- Biochemistry
Background:
- Mutations in Methyl-CpG-binding protein 2 (MeCP2) cause Rett Syndrome, a severe neurodevelopmental disorder.
- MeCP2 is an intrinsically disordered protein crucial for neuronal function.
- Current therapeutic strategies for Rett Syndrome are limited.
Purpose of the Study:
- To develop a protein replacement therapy for Rett Syndrome using MeCP2 fused to a cell-penetrating peptide (TAT).
- To express, purify, and characterize TAT-MeCP2 fusion proteins.
- To evaluate the intracellular uptake and localization of TAT-MeCP2 constructs.
Main Methods:
- Expression and purification of TAT-MeCP2 and TAT-MeCP2-eGFP fusion proteins.
- Characterization of protein stability and aggregation.
- Intracellular uptake studies in human dermal and murine fibroblasts using western blotting and live-cell imaging.
Main Results:
- Purified MeCP2 samples demonstrated high stability and low aggregation.
- Full-length and minimal TAT-MeCP2-eGFP constructs efficiently transduced into fibroblasts.
- Transduced proteins were successfully localized to the cell nuclei.
Conclusions:
- TAT-mediated delivery of MeCP2 is a viable strategy for intracellular protein replenishment.
- MeCP2-based protein replacement therapy shows potential as a treatment for Rett Syndrome.
- Further research into this therapeutic approach is warranted.
